The first participant has been treated in a clinical trial investigating the use of focused ultrasound histotripsy plus immunotherapy to address metastatic or unresectable cancer.
The Foundation is co-funding treatment of the first six participants in the study.
The company’s Edison system will be installed at Hong Kong University and the Chinese University of Hong Kong.
The devices were purchased with a generous donation from the Li Ka Shing Foundation, a philanthropic organization responsible for more than hk$30 billion in education, medical services, charity, and anti-poverty projects.
“When your child is enduring treatment for high risk neuroblastoma, what they are experiencing is essentially every toxic modality of cancer care. It is one of the most brutal treatment regimens that any cancer patient can endure. And it just makes you long for something that is less toxic and more effective. And I think focused ultrasound holds that promise.”